Application of observational research methods to real-world studies for rare disease drugs: A scoping review protocol
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0304540 ↗Kurz gefasst
Scoping Review in der Zeitschrift PLOS ONE, 2025. Verfasst von Yuti P Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Rare Diseases, Observational Studies as Topic. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The primary objective is to identify which observational research methods have been used in the last 5 years in rare disease drug evaluation and how they are applied to generate adequate evidence regarding the real-world effectiveness or safety of rare disease drugs. Rare disease is an umbrella term for a condition which affects < 200,000 people each year and despite the rarity of these conditions, collectively they encompass approximately 7000 different conditions. With the striking number of rare conditions, many pharmaceutical manufacturers are introducing an increased number of drugs to treat them. However, due to small patient populations, heterogeneity and other factors related to rare diseases, there are feasibility concerns regarding the generation of adequate efficacy and safety evidence using conventional randomized controlled trials (RCTs). Recently, real-world evidence generated through observational (or real-world) studies has been proposed to address some of the feasibility concerns with RCTs by measuring drug effectiveness or safety in the real-world setting. However, there remain methodological concerns due to a lack of randomization/masking. This proposed scoping review aims to identify which observational research methods in the last 5 years are used in rare disease drug evaluation to address methodological concerns and how they are applied to generate evidence on drug effectiveness or safety. Articles must be primary observational or real-world studies reporting rare disease drug effectiveness or safety published within the five years preceding this review. Literature reviews, meta-analyses, randomized control trials, case series, case reports, opinion pieces, conference abstracts, and studies with unavailable full-text articles will be excluded. The search strategy will combine the following key search concepts: rare disease, drugs for rare disease and observational/real-world studies. The search will be conducted in MEDLINE and EMBASE. Review registration number : Open Science Framework, https://osf.io/f3wpv
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
- Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada.
ORCID-Profile: Yuti P Patel, Lee Dupuis, Mina Tadrous
Zitieren
APA
Patel, Y. P., Ghaddar, L., Lin, Y., Karim, N., Chan, K., Dupuis, L., & Tadrous, M. (2025). Application of observational research methods to real-world studies for rare disease drugs: A scoping review protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0304540
Vancouver
Patel YP, Ghaddar L, Lin Y, Karim N, Chan K, Dupuis L, et al. Application of observational research methods to real-world studies for rare disease drugs: A scoping review protocol. PLOS ONE. 2025. doi:10.1371/journal.pone.0304540
BibTeX
@article{Patel2025,
author = {Patel, Yuti P and Ghaddar, Lea and Lin, Yuqi and Karim, Nuzat and Chan, Kelvin and Dupuis, Lee and Tadrous, Mina},
title = {Application of observational research methods to real-world studies for rare disease drugs: A scoping review protocol},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0304540}
}
EUVIMED